Abiopharma

Mandatory Warrant Exercise :

Mandatory Warrant Exercise :

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Notification Form for Director in respect of Interests in Securities

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Interest / Changes in Interest - Lim Wee Kian

Financial Statements and Related Announcement: Profit Guidance

General Announcement: Notice to Warrantholders - Expiry of Warrants on 29 June 2026

United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion

Collective Mining Discovers a New Tungsten Enriched High-Grade Subzone 300 Meters Below Surface at Apollo by Drilling 27.35 m at 37.55 g/t AuEq (1.68% WO3, 11.62 g/t Au, 54 g/t Ag, 0.43% Cu)

Midnight Sun Continues Rapid Strike Expansion at Dumbwa; Now 6.7 Kilometres of Near-Surface Copper Mineralization

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia